| abstract |
(57) [Summary]nThe invention features a formulation of indolinone, wherein the compound is ionizable as a free acid or base. The formulation is suitable for parenteral or oral administration, wherein the formulation comprises an ionizable substituted indolinone, and a pharmaceutically acceptable carrier thereof. The term "ionizable substituted indolinone" refers to an optionally substituted both pyrrole and 2-indolinone portion of a compound, as well as being substituted by one or more hydrocarbon chains in the pyrrole moiety. The hydrocarbon contains a pyrrole-substituted 2-indolinone which itself must be substituted with at least one polar group. The formulations and compounds themselves are useful for treating the protein kinase-related disorders described herein. |